Sysmex (OTCMKTS:SSMXY) Lowered to Strong Sell Rating by Zacks Research

Zacks Research cut shares of Sysmex (OTCMKTS:SSMXY) from a hold rating to a strong sell rating in a research report released on Tuesday,Zacks.com reports.

Separately, Citigroup cut Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Sysmex Stock Performance

Shares of SSMXY opened at $9.43 on Tuesday. The stock has a market capitalization of $5.94 billion, a P/E ratio of 24.82 and a beta of 1.07. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. Sysmex has a 1 year low of $8.01 and a 1 year high of $18.10. The company’s fifty day moving average is $8.91 and its two-hundred day moving average is $9.07.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $877.92 million during the quarter, compared to analyst estimates of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, sell-side analysts predict that Sysmex will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.